Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoadjuvant Operable Breast Cancer × Letrozole × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 309 Neoplasm Metastasis 18 Neoplasms 8 Advanced Breast Cancer 8 Carcinoma, Intraductal, Noninfiltrating 6 Breast Neoplasms, Male 6 Triple Negative Breast Neoplasms 5 Osteoporosis 5 Carcinoma, Ductal, Breast 5 Hereditary Sensory and Autonomic Neuropathies 4 Carcinoma, Lobular 4 Breast Diseases 4 Breast Carcinoma In Situ 4 Breast Cancer Metastatic 4 Arthralgia 4 Recurrence 3 Prostatic Neoplasms 3 Neoplasms, Hormone-Dependent 3 Squamous Cell Carcinoma of Head and Neck 2 Pain 2 Ovarian Neoplasms 2 Obesity 2 Multiple Endocrine Neoplasia Type 1 2 Head and Neck Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Endometrial Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients. 1 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡